Screener
Denali Therapeutics Inc. DNLI Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
FAQ
- What is Denali Therapeutics Inc.'s total equity?
- Denali Therapeutics Inc. (DNLI) reported total equity of $835.18M in Q2 2026.
- How has Denali Therapeutics Inc.'s total equity changed year-over-year?
- Denali Therapeutics Inc.'s total equity decreased by 18.7% year-over-year, from $1.03B to $835.18M.
- What is the long-term trend for Denali Therapeutics Inc.'s total equity?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s total equity has grown at a -2.5% compound annual growth rate (CAGR), from $1.15B to $1.01B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Denali Therapeutics Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude